Delpharm

🗓️ 𝐒𝐚𝐯𝐞 𝐭𝐡𝐞 𝐃𝐚𝐭𝐞 - 𝐂𝐏𝐡𝐈 𝐀𝐦𝐞𝐫𝐢𝐜𝐚𝐬 𝟐𝟎𝟐𝟓 #Delpharm is gearing up for CPhI Americas 2025 in Philadelphia, happening from May 20th to 22th.   Our team is excited to engage with you and delve into discussions about your development and manufacturing initiatives. 💡🤝   Reach out to us through our website to schedule a meeting during the event: https://lnkd.in/dwn_qsp   #CDMO #USPharmaMarket #CPHIAmericas2025  

Joseph THIBAUT is newly appointed as Cluster Head focusing on sterile sites. His mission will be to drive sites to deliver manufacturing performance to provide medicines to the patients and satisfy our customers. Joseph has more than 20 years of experience in the Pharmaceutical Industry, managing various pharmaceutical sites in France and mainly abroad such as United Kingdom, Pakistan, Algeria. He will report to Nicolas Leforestier, Chief Operating Officer. #Delpharm #careers #healthcare

🚨 𝐑𝐞𝐩𝐥𝐚𝐜𝐢𝐧𝐠 𝐓𝐢𝐎𝟐 𝐢𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬: 𝐀 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐃𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐟𝐨𝐫 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐋𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐢𝐞𝐬 🚨 Since the ban on TiO2 in food supplements in August 2022, the question of replacing this crucial excipient in medicines has become increasingly urgent. Should the composition be reformulated or adapted? The answer depends on several key factors: 🔹 Pharmaceutical form: coated tablets, capsules, etc. 🔹 Role of TiO2: whitening, opacification, or UV light protection. 🔹 Retaining the original colour: is it essential for the final product? The solutions offered include either the complete removal of TiO2 or its replacement with another excipient. The best solution depends on each project and involves anticipating and adapting the formulas to meet regulatory challenges and ensure the quality of medicines. 🔬 Contact us to discuss: development@delpharm.com #regulatory #biotech #startup #delpharm

📢 𝐃𝐞𝐥𝐩𝐡𝐚𝐫𝐦 𝐢𝐧𝐯𝐞𝐬𝐭𝐬 𝐡𝐞𝐚𝐯𝐢𝐥𝐲 𝐢𝐧 𝐢𝐭𝐬 𝐁𝐨𝐮𝐜𝐡𝐞𝐫𝐯𝐢𝐥𝐥𝐞 𝐬𝐢𝐭𝐞 On Tuesday 18th March, a press conference was held at the Delpharm Boucherville site. The event provided an opportunity to present how #Delpharm will modernize its facilities and perpetuate the manufacture of sterile injectable drugs at its Boucherville site, thanks in particular to a C$200 million investment including C$60 million contribution from the Canadian federal government and the signing of a 10-year commercial agreement with Sandoz. DELPHARM BOUCHERVILLE is a major player in the supply of essential injectable products for surgery and intensive care for Canadian patients. In fact, the plant currently produces 20 of the 100 drugs listed as critical to the Canadian healthcare system. 👉 For more information, download Delpharm presse release: https://lnkd.in/gZA4Bv37 #management #investing #healthcare

𝐎𝐧 𝐭𝐡𝐢𝐬 𝐝𝐚𝐲, 𝐌𝐚𝐫𝐜𝐡 𝟐𝟏𝐬𝐭, 𝐭𝐡𝐞 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐃𝐚𝐲 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐄𝐥𝐢𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐑𝐚𝐜𝐢𝐚𝐥 𝐃𝐢𝐬𝐜𝐫𝐢𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧, 𝐰𝐞 𝐰𝐚𝐧𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐦𝐢𝐧𝐝 𝐞𝐯𝐞𝐫𝐲𝐨𝐧𝐞 𝐭𝐡𝐚𝐭 𝐚𝐭 𝐃𝐞𝐥𝐩𝐡𝐚𝐫𝐦, 𝐰𝐞 𝐛𝐞𝐥𝐢𝐞𝐯𝐞 𝐭𝐡𝐚𝐭 𝐞𝐯𝐞𝐫𝐲𝐨𝐧𝐞 𝐝𝐞𝐬𝐞𝐫𝐯𝐞𝐬 𝐫𝐞𝐬𝐩𝐞𝐜𝐭, 𝐞𝐪𝐮𝐚𝐥𝐢𝐭𝐲 𝐚𝐧𝐝 𝐝𝐢𝐠𝐧𝐢𝐭𝐲, 𝐫𝐞𝐠𝐚𝐫𝐝𝐥𝐞𝐬𝐬 𝐨𝐟 𝐭𝐡𝐞𝐢𝐫 𝐨𝐫𝐢𝐠𝐢𝐧, 𝐬𝐤𝐢𝐧 𝐜𝐨𝐥𝐨𝐫 𝐨𝐫 𝐜𝐮𝐥𝐭𝐮𝐫𝐞. As a responsible company, we are committed to promoting an inclusive environment and actively combating all forms of discrimination. Our actions for inclusion and diversity: 🔹𝐄𝐪𝐮𝐚𝐥 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬: We guarantee hiring and career development conditions based solely on skills and merit. 🔹𝐂𝐮𝐥𝐭𝐮𝐫𝐚𝐥 𝐝𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲: With a presence in several countries, we celebrate the diverse backgrounds and experience of our employees.   Eliminating racial discrimination requires concrete, ongoing action. Today and every day, we affirm our commitment to building a future that is fair, inclusive and respectful of differences. #Delpharm #culture #humanressources

📢 𝐃𝐞𝐥𝐩𝐡𝐚𝐫𝐦 𝐢𝐧𝐯𝐞𝐬𝐭𝐬 𝐡𝐞𝐚𝐯𝐢𝐥𝐲 𝐢𝐧 𝐢𝐭𝐬 𝐁𝐨𝐮𝐜𝐡𝐞𝐫𝐯𝐢𝐥𝐥𝐞 𝐬𝐢𝐭𝐞 On Tuesday 18th March, a press conference was held at the Delpharm Boucherville site. The event provided an opportunity to present how #Delpharm will modernize its facilities and perpetuate the manufacture of sterile injectable drugs at its Boucherville site, thanks in particular to a C$200 million investment including C$60 million contribution from the Canadian federal government and the signing of a 10-year commercial agreement with Sandoz. DELPHARM BOUCHERVILLE is a major player in the supply of essential injectable products for surgery and intensive care for Canadian patients. In fact, the plant currently produces 20 of the 100 drugs listed as critical to the Canadian healthcare system. 👉 For more information, download Delpharm presse release: https://lnkd.in/gZA4Bv37 #management #investing #healthcare

🚀 𝐌𝐞𝐞𝐭 𝐃𝐞𝐥𝐩𝐡𝐚𝐫𝐦 𝐚𝐭 𝐃𝐂𝐀𝐓 𝐖𝐞𝐞𝐤 𝟐𝟎𝟐𝟓! 📅 𝐌𝐚𝐫𝐜𝐡 𝟏𝟕-𝟐𝟎 | 📍 𝐋𝐨𝐭𝐭𝐞 𝐍𝐞𝐰 𝐘𝐨𝐫𝐤 𝐏𝐚𝐥𝐚𝐜𝐞 Are you attending DCAT Week 2025 in New York? Let’s connect! Delpharm will be present, and we would love to meet with you to discuss how we can support your pharmaceutical projects. 𝐎𝐮𝐫 𝐞𝐱𝐩𝐞𝐫𝐭𝐢𝐬𝐞 𝐚𝐜𝐫𝐨𝐬𝐬 𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐝𝐨𝐬𝐚𝐠𝐞 𝐟𝐨𝐫𝐦𝐬: ✅ Sterile Forms – Prefilled syringes (PFS), vials, ampoules, and freeze-drying (lyophilization) ✅ High Potent & Oncology – Manufacturing of solids, liquids, and semi-solids up to OEB5 ✅ Nasal Sprays & Semi-Solids – Advanced capabilities in creams, ointments, gels, and suppositories ✅ Oral Solids – Tablets (film/sugar-coated, bi-layer, effervescent), capsules, pellets, powders, and granules ✅ Liquids & Suspensions – Oral solutions, syrups, drops, and topical sprays ✅ Softgel Capsules – High potent and standard formulations ✅ Microspheres & Complex Injectables – Advanced long-acting formulations ✅ Sachets – Expertise in granules and powders for single-dose packaging ✅ Development Services – Full support from formulation to regulatory approval Delpharm is your CDMO partner of choice for a wide range of sterile, solid, liquid, and semi-solid drug forms, including high potent compounds, sachets, and complex formulations. 📅 𝐒𝐜𝐡𝐞𝐝𝐮𝐥𝐞 𝐚 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐢𝐧 𝐚𝐝𝐯𝐚𝐧𝐜𝐞 𝐚𝐭 𝐝𝐞𝐥𝐩𝐡𝐚𝐫𝐦.𝐝𝐜𝐚𝐭@𝐝𝐞𝐥𝐩𝐡𝐚𝐫𝐦.𝐜𝐨𝐦. We look forward to seeing you in New York! 🌎💊 #DCATWeek2025 #CDMO #healthcare

𝐋𝐨𝐨𝐤𝐢𝐧𝐠 𝐟𝐨𝐫 𝐚 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐥𝐞 𝐂𝐃𝐌𝐎 𝐢𝐧 𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚? With 100% renewable electricity, Delpharm Montréal is your next sustainable partner. With a highly qualified teams, the site is ready to manufacture and package your next projects in nasal sprays, semi-solids and liquids. 👉 To know more, visit Delpharm website: https://lnkd.in/dzUqUaV

🚨 𝐑𝐞𝐩𝐥𝐚𝐜𝐢𝐧𝐠 𝐓𝐢𝐎𝟐 𝐢𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬: 𝐀 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐃𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐟𝐨𝐫 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐋𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐢𝐞𝐬 🚨 Since the ban on TiO2 in food supplements in August 2022, the question of replacing this crucial excipient in medicines has become increasingly urgent. Should the composition be reformulated or adapted? The answer depends on several key factors: 🔹 Pharmaceutical form: coated tablets, capsules, etc. 🔹 Role of TiO2: whitening, opacification, or UV light protection. 🔹 Retaining the original colour: is it essential for the final product? The solutions offered include either the complete removal of TiO2 or its replacement with another excipient. The best solution depends on each project and involves anticipating and adapting the formulas to meet regulatory challenges and ensure the quality of medicines. 🔬 Contact us to discuss: development@delpharm.com #regulatory #biotech #startup #delpharm

𝐌𝐞𝐞𝐭 𝐃𝐞𝐥𝐩𝐡𝐚𝐫𝐦 𝐚𝐭 𝐁𝐢𝐨 𝐄𝐮𝐫𝐨𝐩𝐞 𝐒𝐩𝐫𝐢𝐧𝐠 𝟐𝟎𝟐𝟓 𝐟𝐫𝐨𝐦 𝐌𝐚𝐫𝐜𝐡 𝟏𝟕-𝟏𝟗 𝐚𝐭 𝐌𝐢𝐥𝐚𝐧, 𝐈𝐭𝐚𝐥𝐲. Our development BD team will be pleased to discuss your development projects and meet at our booth 56. 📧 To schedule a meeting with us, please send us a message via PartneringOne or via email at development@delpharm.com. #Delpharm #BioEuropeSpring